Triglav Skladi D.O.O. Invests $727,000 in Zoetis Inc. (NYSE:ZTS)

Triglav Skladi D.O.O. acquired a new position in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,460 shares of the company’s stock, valued at approximately $727,000.

Several other institutional investors have also recently made changes to their positions in the business. Mission Wealth Management LP lifted its stake in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. increased its holdings in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after acquiring an additional 62 shares in the last quarter. HUB Investment Partners LLC increased its holdings in Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock worth $224,000 after acquiring an additional 62 shares in the last quarter. Procyon Advisors LLC increased its holdings in Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after acquiring an additional 63 shares in the last quarter. Finally, Coppell Advisory Solutions LLC increased its holdings in Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock worth $68,000 after acquiring an additional 64 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 1.7%

ZTS stock opened at $163.03 on Monday. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $72.58 billion, a price-to-earnings ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. The business has a 50 day simple moving average of $156.46 and a two-hundred day simple moving average of $165.22.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the prior year, the company posted $1.38 EPS. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ZTS. Barclays increased their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Stifel Nicolaus reduced their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus price target of $212.75.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.